跳到主要內容區塊
Google  

 

 

:::

[2020/10/16] NYMU New Drug Technology for “Non-Alcoholic Fatty Liver Disease” and “Intelligent Video-Assisted Needle Puncture” won the MOST ” 2020 Future Technology Breakthrough Award”

Professor Tsai (right 3rd) and her team receiving the award

 

The innovative technology developed by Professor Tsai and her team is the “Cisd2 Activator: A Novel Treatment Method for Non-Alcoholic Fatty Liver and Steatohepatitis”. Professor Tsai said, “Non-alcoholic fatty liver disease is a collective term for excessive accumulation of liver fat leading to extensive liver cell degeneration. It is a common chronic liver disease worldwide, and its prevalence accounts for 20-30% of the general population worldwide. However, there are currently no approved drugs that can effectively treat non-alcoholic fatty liver”.

 

Professor Tsai (middle) and program co-host Professor Lin (left second) and members of the research team.

 

Professor Tsai’s team discovered from previous studies that if the Cisd2 longevity gene expression declines, it will lead to non-alcoholic fatty liver and hepatitis. With only half or less amount of Cisd2 protein, it will be difficult to maintain normal liver function, leading to fatty liver and liver inflammation. Therefore, the development of a Cisd2 activator that can promote Cisd2 expression may improve non-alcoholic fatty liver disease and hepatitis.

 

The innovative technology developed by Professor Tsai’s team uses diverse small molecule library screening and structural optimization strategies to obtain a potential “Cisd2 activator”. Such method is different from the current developed non-alcoholic fatty liver disease/hepatitis drug target. Professor Tsai’s technology is expected to become an original innovative drug. If it is successfully developed, not only will it be expected to bring a new dawn to the treatment of such patients, but also in the potential drug competition with a market scale of about 35 billion US dollars. The uniqueness, novelty and necessity of Cisd2 activator will be the key to cutting into this pie.

 

Professor Guo (middle) and his team receiving the award

 

Professor Guo’s team mainly develops portable, non-contact, ionizing radiation-free, and high-resolution intravital optical sectioning techniques that do not require fluorescent cursor positioning. It can provide intravital tomography with different observation scales from 1 to 15 microns, and the highest image capture rate is about 400 frames per second. It has been used in pre-clinical live small animal measurements to human ophthalmology, dermatology, digestive tract and other different clinical medical fields and completed a number of technical transfers.

 

Professor Guo pointed out that because there are many procedures in clinical medical treatments that require tissue puncture using different types of needles (such as epidural anesthesia, laparoscopic surgery, and skull drilling, etc.) These procedures can cause multiple complications every year around the world. Therefore, precision medicine will improve the accuracy of medical diagnosis and treatment of surgery.

 

The prototype machine of the intelligent video-assisted needle puncture system exhibited at the “Future Technology Exhibition”

 

Professor Guo’s team’s award-winning technology “Intelligent Video-Assisted Guided Needle Puncture” uses the principle of high-resolution intravital laser optical sectioning. It uses a lens of less than 1mm combined with No. 14 to No. 18 needles, which can instantly display the tissue slice where the needle is located. The images are then classified by machine learning methods to automatically identify the needle position to achieve precision positioning and safety requirements. Such can greatly reduce the failure rate of traditional puncture needles and other complications. This technology has obtained Taiwan and the United States invention patents and completed the development of prototype products. It has also completed preclinical animal experiments for epidural anesthesia and laparoscopic minimally invasive surgery. The next step will be human trials.

 

 

 

 

 

 

 

 

 

 

 


 

views